Williamsburg Dialysis in Williamsburg, Virginia - Dialysis Center

Williamsburg Dialysis is a medicare approved dialysis facility center in Williamsburg, Virginia and it has 16 dialysis stations. It is located in James City county at 500 Sentara Cir Ste 103, Williamsburg, VA, 23188. You can reach out to the office of Williamsburg Dialysis at (757) 206-1408. This dialysis clinic is managed and/or owned by Davita. Williamsburg Dialysis has the following ownership type - Profit. It was first certified by medicare in September, 2007. The medicare id for this facility is 492651 and it accepts patients under medicare ESRD program.

Dialysis Center Profile

NameWilliamsburg Dialysis
Location500 Sentara Cir Ste 103, Williamsburg, Virginia
No. of Dialysis Stations 16
Medicare ID492651
Managed ByDavita
Ownership TypeProfit
Late Shifts No

Contact Information


500 Sentara Cir Ste 103, Williamsburg, Virginia, 23188
(757) 206-1408

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago


Map and Direction



NPI Associated with this Dialysis Facility:

Dialysis Facilities may have multiple NPI numbers. We have found possible NPI number/s associated with Williamsburg Dialysis from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number1265559769
Organization NameWilliamsburg Dialysis
Doing Business AsRenal Treatment Centers Mid Atlantic Inc
Address500 Sentara Cir Williamsburg, Virginia, 23188
Phone Number(757) 206-1408

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago


NPI Number1366924904
Organization NameMerrimac Trail Dialysis
Doing Business AsOssippee Dialysis Llc
Address469 Merrimac Trl Williamsburg, Virginia, 23185
Phone Number(615) 320-4491

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago


Survey of Patient's Experiences

Nephrologists Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that nephrologists always communicated and cared for them.55%67%
Patients who reported that nephrologists usually communicated and cared for them.18%15%
Patients who reported that nephrologists sometimes or never communicated and cared for them.27%18%
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).56%60%
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).28%26%
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).16%14%

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago

Dialysis Center Staff Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible.49%62%
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible.21%20%
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free.30%18%
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).48%62%
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).26%26%
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).26%12%

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago

Overall Dialysis Center Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. 78%80%
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them.22%20%
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).53%68%
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).23%20%
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).24%12%

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago

Patient Distribution

Anemia Management

Dialysis patients with Hemoglobin data71
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL17

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago

Dialysis Adequacy

Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.

  • Hemodialysis
    Adult patients getting regular hemodialysis at the center95
    Adult patient months included in Kt/V greater than or equal to 1.2822
    Percentage of adult patients getting regular hemodialysis at the center93
    Percentage of pediatric patients getting regular hemodialysis at the center

    News Archive

    Antisense oligonucleotides engineered to inhibit SARS-CoV-2

    In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

    FDA accepts NDA review for new anticonvulsant drug

    The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

    Stem cell treatment: A new hope for Multiple Sclerosis

    RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

    The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

    A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

    Read more Medical News

    › Verified 7 days ago

  • Peritoneal Dialysis
    Adult patients getting regular peritoneal dialysis at the center19
    Adult patient months included in Kt/V greater than or equal to 1.7150
    Percentage of adult patients getting regular peritoneal dialysis at the center91
    Percentage of pediatric patients getting regular peritoneal dialysis at the center

    News Archive

    Antisense oligonucleotides engineered to inhibit SARS-CoV-2

    In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

    FDA accepts NDA review for new anticonvulsant drug

    The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

    Stem cell treatment: A new hope for Multiple Sclerosis

    RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

    The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

    A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

    Read more Medical News

    › Verified 7 days ago

Mineral and Bone Disorder

An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Williamsburg Dialysis with elevated calcium levels.

Patients with hypercalcemia123
Hypercalcemia patient months1120
Hypercalcemia patients with serumcalcium greater than 10.2 mg1
Patients with Serumphosphor126
Patients with Serumphosphor less than 3.5 mg/dL13
Patients with Serumphosphor from 3.5 to 4.5 mg/dL30
Patients with Serumphosphor from 4.6 to 5.5 mg/dL32
Patients with Serumphosphor from 5.6 to 7 mg/dL15
Patients with Serumphosphor greater than 7 mg/dL9

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago

Vascular Access

The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.

Patients included in arterial venous fistula and catheter summaries 182
Patient months included in arterial venous fistula and catheter summaries 842
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment58
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer10

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago

Hospitalization Rate

The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.

Standard Hospitalization Summary Ratio(SHR) YearJanuary, 2016 - December, 2016
Patients in facility's Hospitalization Summary87
Hospitalization Rate in facility163.1 (As Expected)
Hospitalization Rate: Upper Confidence Limit285.6
Hospitalization Rate: Lower Confidence Limit101.3

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago

Readmission Rate

The rate of readmission show you whether patients who were being treated regularly at Williamsburg Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.

Standard Readmission Summary Ratio(SRR) YearJanuary, 2016 - December, 2016
Readmission Rate in facility21.3 (As Expected)
Readmission Rate: Upper Confidence Limit30.2
Readmission Rate: Lower Confidence Limit14

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago

Infection Rate

Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Williamsburg Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.

Standard Infection Summary Ratio(SIR) YearJanuary, 2016 - December, 2016
Infection Rate in facility.18 (Better than Expected)
SIR: Upper Confidence Limit.91
SIR: Lower Confidence Limit.01

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago

Transfusion Summary

Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Williamsburg Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.

Standard Transfusion Summary Ratio (STrR) Year January, 2016 - December, 2016
Patients in facility's Transfusion Summary 77
Transfusion Rate in facility36.5 (As Expected)
Transfusion Rate: Upper Confidence Limit78.9
Transfusion Rate: Lower Confidence Limit18.6

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago

Survival Summary

The rate of mortality show you whether patients who were being treated regularly at Williamsburg Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.

Standard Survival Summary Ratio(SIR) YearJanuary, 2013 - December, 2016
Patients in facility's Survival Summary493
Mortality Rate in facility14.7 (As Expected)
Mortality Rate: Upper Confidence Limit19.1
Mortality Rate: Lower Confidence Limit11.1

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago


Dialysis Facility in Williamsburg, VA

RAI - John Tyler Hwy-Williamsburg
Location: 6726 Mooretown Road, Williamsburg, Virginia, 23188
Phone: (757) 229-5701
Williamsburg Dialysis
Location: 500 Sentara Cir Ste 103, Williamsburg, Virginia, 23188
Phone: (757) 206-1408

News Archive

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

FDA accepts NDA review for new anticonvulsant drug

The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) seeking marketing approval for Retigabine. In addition, the European Medicines Agency (EMEA) confirmed on November 17, 2009 that the MAA (Marketing Authorization Application) was successfully validated thus enabling the MAA review to commence.

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

Read more Medical News

› Verified 7 days ago


Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.